Study Objective: The aim of this study was to estimate the rate of intrauterine adhesions and subsequent pregnancy outcome in patients with residual trophoblastic tissue treated with hysteroscopic resection versus ultrasound-guided dilation and evacuation (D&E).
Design: Cohort study from 2 centers (Canadian Task Force classification II-2).
Setting: Two surgical teams at the University of Duesseldorf Medical Center and the PAN Clinic in Cologne, Germany.
Patients: Women with residual trophoblastic tissue after first- or second-trimester miscarriage or term delivery.
Intervention: Two techniques were used for the removal of residual trophoblastic tissue: ultrasound-guided evacuation with a curette (D&E) and hysteroscopic resection of trophoblastic tissue (HR).
Measurements And Main Results: We evaluated 95 patients who underwent secondary intervention for residual trophoblastic disease. A total of 42 patients underwent dilation of the cervix and ultrasound-guided curettage. In a second series of 53 patients, a resectoscope fitted with a 4-mm cutting loop was used for the removal of residual trophoblastic tissue used without application of current. Three months after the intervention, second-look office hysteroscopy was performed. Differences between both treatment groups were statistically significant. After HR, mild intrauterine adhesions were found in 2 patients (4.2%). After D&E, 12 patients (30.8%) presented with intrauterine adhesions (mild intrauterine adhesions: n = 7 [17.9%]; single dense adhesions: n = 3 [7.7%]; and extensive endometrial fibrosis n = 1 [2.6%]). Eighty-two patients wanted to become pregnant. Conception rate of all patients examined was 68.8% (HR) and 59.9% (D&E) (p < .05). In patients younger than 35 years of age who underwent HR, the pregnancy rate was significantly (p < .05) increased compared with patients who underwent D&E (78.1% vs 66.6%). In addition, patients from the HR group demonstrated a significantly (p < .05) shorter time to conception (11.5 month vs 14.5 month).
Conclusion: The results of this study indicate that selective HR of residual trophoblastic tissue significantly reduces the incidence of intrauterine adhesions and increases pregnancy rates.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jmig.2011.08.003 | DOI Listing |
Fertil Steril
November 2024
Obstetrics, Gynecology, and Reproductive Sciences Department, Minimally Invasive Gynecology Division, University of Miami, Miller School of Medicine, Miami, Florida.
Objective: To describe the technique of embryofetoscopy performed with 5Fr instruments with targeted evacuation of the gestational sac followed by a visual dilatation and curettage (D&C) using the hysteroscopic tissue removal system for the management of first trimester missed abortion in a patient with uterine septum.
Design: Video case-report.
Setting: University tertiary-care hospital.
J Clin Med
July 2024
Department of Obstetrics and Gynecology, Division of Obstetrics and Feto-Maternal Medicine, Medical University of Vienna, 1090 Vienna, Austria.
Retained products of conception after childbirth or miscarriage are associated with an increased rate of maternal complications, such as abnormal vaginal bleeding and infections. Late complications may also include intrauterine adhesions, causing infertility. Surgical interventions carry a certain risk.
View Article and Find Full Text PDFJ Ultrasound
December 2024
Department of Radiodiagnosis, All India Institute of Medical Sciences (AIIMS), Raipur, 492001, Chhattisgarh, India.
Ther Adv Med Oncol
April 2024
The University of Kansas Medical Center, Kansas City, KS, USA.
Background: Despite advances in the treatment of early triple-negative breast cancer (TNBC), patients with residual invasive disease after neoadjuvant therapy have a high risk of disease recurrence and worse survival outcomes than those who have pathological complete response (pCR). Improving outcomes in early TNBC remains an unmet need requiring new adjuvant treatment approaches. Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate comprising a humanized anti-trophoblast cell-surface antigen 2 immunoglobulin G1 (IgG1) monoclonal antibody attached a plasma-stable, cleavable linker to a potent topoisomerase I inhibitor payload, with activity observed in advanced TNBC.
View Article and Find Full Text PDFDev Cell
July 2024
Department of Obstetrics and Gynecology, Women and Children's Hospital of Chongqing Medical University, Chongqing 401147, China; Chongqing Key Laboratory of Maternal and Fetal Medicine, Chongqing Medical University, Chongqing 400016, China; Joint International Research Laboratory of Reproduction and Development of Chinese Ministry of Education, Chongqing Medical University, Chongqing 400016, China. Electronic address:
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!